An interventional study of An iLN interactive teaching platform and PPT in Learning, sponsored by Nanjing University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Nanjing University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Lupus Nephritis with a site in China — 43 open to participants now, 46 under way, 8 of them phase 3. Lupus Nephritis · China.
Among the 96 studies in Lupus Nephritis with a site in China, this one is the 45th largest by planned enrollment of the 88 interventional ones that give a count, is one of 11 that started in 2026, is one of 16 with no phase, reaches primary completion later than 16 of the 45 other live ones, and was the 92nd registered.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
Browse Lupus Nephritis studies →43 of the 96 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 6–18
Beijing GoBroad Hospital · Sites in China
Ages 6–65
Beijing Biotech · Sites in China
Ages 18–70
Nanjing University School of Medicine · Sites in China
Ages 14–65
China Immunotech (Beijing) Biotechnology Co., Ltd. · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 31 · Phase 3 22 · Phase 4 7
First in 1996; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Median enrollment 51 across the 88 interventional studies, 400 across the 7 observational. Of the 34 that completed or were terminated, 11 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 96 have an industry lead sponsor. The 10 most frequent:
Nanjing University is the lead sponsor of 21 studies on the registry; 9 are open to participants now.
Nanjing University has 1 study filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
17 of the studies in Lupus Nephritis with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT06406205Phase 3Qilu Pharmaceutical Co., Ltd.A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis | 2027-06 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT07236762China Immunotech (Beijing) Biotechnology Co., Ltd.An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases | 2026-11-24 |
| NCT07706998Nanjing UniversityApplication of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus Nephritis | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 96 studies in Lupus Nephritis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aim:
To evaluate the application effect of the teaching platform iLN in the teaching of lupus nephritis, aiming to provide practical experience and evidence-based support for the implementation of generative AI technology in professional medical education.
Method:
Based on the DeepSeek large language model, the investigators developed "iLN" - an interactive teaching platform for lupus nephritis. This platform integrates the latest authoritative textbooks, clinical guidelines, pathological atlases, and real clinical cases, and includes seven core modules, such as "case interaction", "knowledge teaching", and "AI question answering". The investigators conducted a randomized controlled trial (RCT) on 50 fourth-year undergraduate students from Nanjing University School of Medicine to evaluate the effectiveness of the iLN platform compared to traditional teaching methods. The teaching effect was evaluated through objective test scores and questionnaires about student satisfaction and platform usability.
Artificial Intelligence (AI) technology is reshaping the landscape of medical education with unprecedented depth and breadth. From early rule-based teaching expert systems to the current generation of Generative AI (GAI) systems like ChatGPT and DeepSeek, the continuous evolution of technology has not only greatly enriched teaching methods but also fundamentally changed the ways knowledge is acquired, disseminated, and evaluated. Internationally, Generative AI (GAI) has been widely applied in creating virtual cases, constructing clinical simulation scenarios, assisting medical writing, and providing personalized learning plans for medical students. However, there are almost no dedicated large language model (GAI) teaching applications specifically for lupus nephritis (LN) worldwide. As the most common severe organ complication of systemic lupus erythematosus (SLE), LN affects approximately 50% to 70% of SLE patients with kidney involvement. Its diagnosis and treatment involve multiple complex processes, including the identification of clinical manifestations, the interpretation of immune markers, the assessment of renal pathological types, the quantification of disease activity, and the formulation of personalized treatment plans. All of these place extremely high demands on the knowledge integration and clinical reasoning skills of medical students. The traditional LN teaching model mainly relies on theoretical classroom lectures and is supplemented by static pathological image presentations. Some scholars have introduced problem-based learning (PBL) teaching models and integrated ideological and political education, but there are still significant deficiencies: (1) Knowledge update lag - In the field of LN, new diagnostic standards (such as the 2019 EULAR/ACR systemic lupus erythematosus classification criteria), new pathological classifications (such as the 2018 ISN/RPS revised version), and new drug treatment regimens (such as belimumab) are constantly emerging, while the textbook revision cycle is relatively long, making it difficult for students to obtain the latest knowledge in a timely manner; (2) Lack of personalized teaching - Facing students with varying levels of basic knowledge, teachers find it difficult to meet the needs of different learning paces; students with weak foundations have difficulty understanding complex pathological mechanisms, while those with solid foundations may find the content too simplistic; (3) Insufficient clinical reasoning training - Traditional classrooms lack real clinical scenario simulations, and students listen passively rather than actively exploring, making it difficult for them to establish a complete clinical reasoning chain from "symptoms - signs - laboratory tests - pathology - diagnosis - treatment". In this context, building a GAI-assisted teaching platform specifically designed for LN teaching, fully leveraging the personalized interaction, dynamic content generation, and intelligent assessment capabilities of AI, is of great significance for teaching reform and innovation.
In this study, the investigators constructed an iLN interactive teaching platform for lupus nephritis based on the DeepSeek large language model and by integrating the latest authoritative textbooks, guidelines, and clinical pathology materials. Through a randomized controlled teaching trial, the investigators systematically evaluated the application effect of this platform in LN teaching, aiming to provide practical experience and evidence-based support for the implementation of GAI technology in specialized medical education.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
GAI-assisted teaching group: Students used various platform modules for self-directed learning under the instructor's guidance: (1) In the "Case Interaction" module, students interacted with three virtual cases by inputting natural language questions (e.g., "Does the patient have edema?", "What is the patient's proteinuria level?", "What are the light microscopy results of the renal biopsy?"). The platform automatically determines the question type and provides the corresponding information, while the visualized patient model on the right side simultaneously highlights the affected systems already identified, and the case information acquisition progress bar is updated dynamically; (2) When students encounter difficulties, they can invoke DeepSeek in real time for immediate answers through the "AI Q\&A" module; (3) After completing case interactions, students proactively summarized the history characteristics, with the instructor providing supplementary input; (4) The instructor guided
Device: An iLN interactive teaching platform
Traditional teaching group: Adopted the traditional PowerPoint (PPT) lecture mode. The instructor used uniformly prepared PPT courseware to sequentially lecture on the SLE overview, LN clinical manifestations, laboratory tests, pathological classification, diagnostic criteria, treatment plans, and prognosis evaluation. The courseware included static pathological and clinical manifestation images.
Other: PPT
An iLN interactive teaching platform for lupus nephritis based on the DeepSeek large language model and by integrating the latest authoritative textbooks, guidelines, and clinical pathology materials.
Adopted the traditional PowerPoint (PPT) lecture mode. The instructor used uniformly prepared PPT courseware to sequentially lecture on the SLE overview, LN clinical manifestations, laboratory tests, pathological classification, diagnostic criteria, treatment plans, and prognosis evaluation. The courseware included static pathological and clinical manifestation images.
Objective Test Scores
Unified in-class objective test (20 multiple-choice questions, 5 points each, 100 points total),the higher the score, the better the performance.
Time frame: On the day of the end of the teaching session within 30 minutes after teaching session
Questionnaire Survey
Students in the GAI group filled out the questionnaire on the iLN platform, including overall satisfaction (satisfied/dissatisfied), and gave scores (from 1 to 5) on 12 dimensions such as the platform's interest, teaching novelty, content clarity, interface design, and learning effect improvement. They also submitted open-ended suggestions for improvement.
Time frame: On the day of the end of the teaching session within 60 minutes after teaching session.
Plan to share: No — Individual participant data will not be shared
Start is estimated for Jul 2026; primary completion for Dec 2026, 5 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanjing University